Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial,
Introducing Oncotarget.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
Subscribe to receive alerts once a paper has been published by Oncotarget.
Uri Rozovski, David M. Harris, Ping Li, Zhiming Liu, Preetesh Jain, Taghi Manshouri, Ivo Veletic, Alessandra Ferrajoli, Prithviraj Bose, Phillip Thompson, Nitin Jain, Srdan Verstovsek, William Wierda, Michael J. Keating, Zeev Estrov
Published Jan 30, 2021 · Vol. 12, No. 5 · pp. 401-411
Enric Carcereny, Alonso Fernández-Nistal, Araceli López, Carmen Montoto, Andrea Naves, Cristina Segú-Vergés, Mireia Coma, Guillem Jorba, Baldomero Oliva, Jose Manuel Mas
Published Jan 22, 2021 · Vol. 12, No. 4 · pp. 316-332
Keywords: ALK inhibitor, brigatinib, alectinib, mathematical model, systems biology
Judith E. den Ouden, Guido J.R. Zaman, Jelle Dylus, Antoon M. van Doornmalen, Winfried R. Mulder, Yvonne Grobben, Wilhelmina E. van Riel, Joanne A. de Hullu, Rogier C. Buijsman, Anne M. van Altena
Published Nov 20, 2020 · Vol. 11, No. 49 · pp. 4570-4581